SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2024-03-08 17:46
Tx date 2024-03-04
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-9,000 vol
201,000
Filed 2024-03-08 17:38
Tx date 2024-03-04
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
52 - Expiration of options

-35,000 vol
643,021
Filed 2024-03-08 17:27
Tx date 2024-03-04
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$16,666
+16,666 vol
$1.00 each
247,485
Filed 2024-03-08 17:21
Tx date 2024-03-04
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-16,666
-16,666 vol
$1.00 each
20,000
Filed 2024-03-07 16:31
Tx date 2024-03-07
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$7,800
+15,000 vol
$0.52 each
115,000
Filed 2024-03-07 11:49
Tx date 2024-03-07
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$10,000
+20,000 vol
$0.50 each
1,003,296
Filed 2024-03-06 11:38
Tx date 2024-03-06
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$9,600
+24,000 vol
$0.40 each
254,819
Filed 2024-01-13 16:23
Tx date 2023-10-21
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-7,500 vol
46,251
Filed 2024-01-13 16:19
Tx date 2023-10-21
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Options
52 - Expiration of options

-7,500 vol
65,000
Filed 2024-01-13 16:11
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$12,482
+11,666 vol
$1.07 each
38,334
Filed 2024-01-13 16:10
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-12,482.62
-11,666 vol
$1.07 each
1,666
Filed 2024-01-13 16:07
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$12,482
+11,666 vol
$1.07 each
38,334
Filed 2024-01-13 16:06
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-12,482.62
-11,666 vol
$1.07 each
1,666
Filed 2024-01-13 16:04
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$14,267
+13,334 vol
$1.07 each
333,334
Filed 2024-01-13 16:03
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-14,267.38
-13,334 vol
$1.07 each
1,666
Filed 2024-01-13 16:00
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$42,800
+40,000 vol
$1.07 each
95,334
Filed 2024-01-13 15:59
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-42,800
-40,000 vol
$1.07 each
1,666
Filed 2024-01-13 15:56
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$14,267
+13,334 vol
$1.07 each
185,136
Filed 2024-01-13 15:55
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-14,267.38
-13,334 vol
$1.07 each
1,666
Filed 2024-01-13 15:48
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$12,482
+11,666 vol
$1.07 each
202,819
Filed 2024-01-13 15:47
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-12,482.62
-11,666 vol
$1.07 each
71,666
Filed 2024-01-13 15:43
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Common Shares
57 - Exercise of rights
$22,238
+20,784 vol
$1.07 each
123,209
Filed 2024-01-13 15:42
Tx date 2024-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights
$-22,238.88
-20,784 vol
$1.07 each
75,684
Filed 2023-11-18 15:28
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$5,200
+5,000 vol
$1.04 each
191,153
Filed 2023-11-18 15:27
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-5,200
-5,000 vol
$1.04 each
83,332
Filed 2023-11-18 15:25
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
26,668
Filed 2023-11-18 15:24
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
13,332
Filed 2023-11-18 15:22
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
26,668
Filed 2023-11-18 15:22
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
13,332
Filed 2023-11-18 15:20
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
320,000
Filed 2023-11-18 15:19
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
15,000
Filed 2023-11-18 15:17
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
55,334
Filed 2023-11-18 15:17
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
41,666
Filed 2023-11-18 15:14
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
171,802
Filed 2023-11-18 15:14
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
15,000
Filed 2023-11-18 15:07
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,733
+1,667 vol
$1.04 each
41,700
Filed 2023-11-18 15:07
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,733.68
-1,667 vol
$1.04 each
10,000
Filed 2023-11-18 15:03
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Common Shares
57 - Exercise of rights
$3,466
+3,333 vol
$1.04 each
102,425
Filed 2023-11-18 15:02
Tx date 2023-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights
$-3,466.32
-3,333 vol
$1.04 each
96,468
Filed 2023-09-15 18:29
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
20,000
Filed 2023-09-15 18:26
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
20,000
Filed 2023-09-15 18:24
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
40,000
Filed 2023-09-15 18:18
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
20,000
Filed 2023-09-15 18:15
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
53,751
Filed 2023-09-15 18:11
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
72,500
Filed 2023-09-15 18:08
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+36,000 vol
48,000
Filed 2023-09-15 18:05
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+136,000 vol
248,000
Filed 2023-09-15 17:52
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+108,000 vol
210,000
Filed 2023-09-15 17:49
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+108,000 vol
144,000
Filed 2023-09-15 17:45
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Options
50 - Grant of options

+72,000 vol
72,000
Filed 2023-09-15 17:44
Tx date 2015-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Options
00 - Opening Balance-Initial SEDI Report
Filed 2023-09-15 17:24
Tx date 2023-09-12
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+255,000 vol
678,021
Filed 2023-05-03 13:27
Tx date 2023-05-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,799
+3,333 vol
$0.54 each
40,033
Filed 2023-05-03 13:27
Tx date 2023-05-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-1,799.82
-3,333 vol
$0.54 each
11,667
Filed 2023-05-03 13:23
Tx date 2023-05-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$8,999
+16,666 vol
$0.54 each
186,153
Filed 2023-05-03 13:22
Tx date 2023-05-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-8,999.64
-16,666 vol
$0.54 each
88,332
Filed 2023-03-06 12:18
Tx date 2023-03-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$8,500
+16,667 vol
$0.51 each
169,487
Filed 2023-03-06 12:17
Tx date 2023-03-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-8,500.17
-16,667 vol
$0.51 each
104,998
Filed 2023-01-14 16:02
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$6,883
+11,667 vol
$0.59 each
25,001
Filed 2023-01-14 16:01
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-6,883.53
-11,667 vol
$0.59 each
14,999
Filed 2023-01-14 15:58
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$6,883
+11,667 vol
$0.59 each
25,001
Filed 2023-01-14 15:57
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-6,883.53
-11,667 vol
$0.59 each
14,999
Filed 2023-01-14 15:54
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$7,866
+13,333 vol
$0.59 each
318,333
Filed 2023-01-14 15:53
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-7,866.47
-13,333 vol
$0.59 each
16,667
Filed 2023-01-14 15:50
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$7,866
+13,333 vol
$0.59 each
170,135
Filed 2023-01-14 15:49
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-7,866.47
-13,333 vol
$0.59 each
16,667
Filed 2023-01-14 15:44
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$6,883
+11,667 vol
$0.59 each
152,820
Filed 2023-01-14 15:44
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-6,883.53
-11,667 vol
$0.59 each
121,665
Filed 2023-01-14 15:39
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
57 - Exercise of rights
$12,261
+20,783 vol
$0.59 each
99,092
Filed 2023-01-14 15:37
Tx date 2023-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Restricted Share Units
57 - Exercise of rights
$-12,261.97
-20,783 vol
$0.59 each
99,801
Filed 2022-12-16 22:34
Tx date 2022-12-13
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-44,590
-91,000 vol
$0.49 each
1,522,976
Filed 2022-12-16 22:33
Tx date 2022-12-12
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-77,910
-159,000 vol
$0.49 each
1,613,976
Filed 2022-12-01 22:25
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$22,800
+47,500 vol
$0.48 each
68,918
Filed 2022-12-01 22:23
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-22,800
-47,500 vol
$0.48 each
110,000
Filed 2022-12-01 22:19
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$2,560
+5,334 vol
$0.48 each
305,000
Filed 2022-12-01 22:18
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-2,560.32
-5,334 vol
$0.48 each
30,000
Filed 2022-12-01 22:14
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$24,960
+52,000 vol
$0.48 each
53,667
Filed 2022-12-01 22:13
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-24,960
-52,000 vol
$0.48 each
43,333
Filed 2022-12-01 22:08
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$2,560
+5,334 vol
$0.48 each
156,802
Filed 2022-12-01 22:07
Tx date 2022-11-28
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-2,560.32
-5,334 vol
$0.48 each
30,000
Filed 2022-11-19 13:20
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
13,334
Filed 2022-11-19 13:19
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
26,666
Filed 2022-11-19 13:15
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
5,000
Filed 2022-11-19 13:13
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 13:11
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
13,334
Filed 2022-11-19 13:08
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
26,666
Filed 2022-11-19 13:02
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
5,000
Filed 2022-11-19 13:01
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:58
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
299,666
Filed 2022-11-19 12:57
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
35,334
Filed 2022-11-19 12:55
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
25,000
Filed 2022-11-19 12:52
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+15,000 vol
325,000
Filed 2022-11-19 12:49
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
1,667
Filed 2022-11-19 12:48
Tx date 2018-03-19
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:48
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
95,333
Filed 2022-11-19 12:45
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
5,000
Filed 2022-11-19 12:44
Tx date 2018-03-19
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:41
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
151,468
Filed 2022-11-19 12:41
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
35,334
Filed 2022-11-19 12:38
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
38,751
Filed 2022-11-19 12:35
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+5,000 vol
57,500
Filed 2022-11-19 12:29
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$800.16
+1,667 vol
$0.48 each
36,700
Filed 2022-11-19 12:28
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-800.16
-1,667 vol
$0.48 each
15,000
Filed 2022-11-19 12:24
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+12,000 vol
12,000
Filed 2022-11-19 12:23
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 12:20
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+42,000 vol
112,000
Filed 2022-11-19 12:10
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+36,000 vol
102,000
Filed 2022-11-19 12:05
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$2,400
+5,000 vol
$0.48 each
127,623
Filed 2022-11-19 12:04
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights
$-2,400
-5,000 vol
$0.48 each
133,332
Filed 2022-11-19 12:00
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+36,000 vol
36,000
Filed 2022-11-19 11:58
Tx date 2020-05-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2022-11-19 11:54
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Common Shares
57 - Exercise of rights
$1,599
+3,333 vol
$0.48 each
78,309
Filed 2022-11-19 11:53
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights
$-1,599.84
-3,333 vol
$0.48 each
120,584
Filed 2022-11-19 11:46
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+24,000 vol
94,000
Filed 2022-11-19 11:41
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+85,000 vol
423,021
Filed 2022-11-16 20:05
Tx date 2022-11-16
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,897
+13,530 vol
$0.362 each
136,153
Filed 2022-11-16 19:56
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$19,400
+40,000 vol
$0.485 each
983,296
Filed 2022-11-16 19:50
Tx date 2022-11-15
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$10,000
+20,000 vol
$0.50 each
100,000
Filed 2022-08-19 14:12
Tx date 2022-08-16
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$1,716
+3,300 vol
$0.52 each
122,623
Filed 2022-08-19 14:11
Tx date 2022-08-16
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,384
+8,120 vol
$0.54 each
119,323
Filed 2022-08-19 14:09
Tx date 2022-08-16
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,335
+8,500 vol
$0.51 each
111,203
Filed 2022-07-20 18:50
Tx date 2022-07-15
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-3,100
-5,000 vol
$0.62 each
1,772,976
Filed 2022-07-14 21:06
Tx date 2022-02-27
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
55 - Expiration of warrants

-4,000 vol
1,750
Filed 2022-07-13 13:50
Tx date 2022-06-16
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Warrants
38 - Redemption, retraction, cancellation, repurchase

-8,333 vol
0
Filed 2022-07-13 13:47
Tx date 2022-06-16
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
38 - Redemption, retraction, cancellation, repurchase

-1,750 vol
4,000
Filed 2022-07-12 20:04
Tx date 2022-07-12
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-18,910
-30,500 vol
$0.62 each
1,777,976
Filed 2022-07-12 20:04
Tx date 2022-07-11
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-25,730
-41,500 vol
$0.62 each
1,808,476
Filed 2022-07-12 20:03
Tx date 2022-07-11
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-12,000
-20,000 vol
$0.60 each
1,849,976
Filed 2022-07-12 20:02
Tx date 2022-07-08
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-5,270
-8,500 vol
$0.62 each
1,869,976
Filed 2022-07-12 20:01
Tx date 2022-07-08
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-3,111
-5,100 vol
$0.61 each
1,878,476
Filed 2022-07-12 20:00
Tx date 2022-07-08
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-9,600
-16,000 vol
$0.60 each
1,883,576
Filed 2022-07-12 19:59
Tx date 2022-07-07
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-13,330
-21,500 vol
$0.62 each
1,899,576
Filed 2022-07-12 19:47
Tx date 2022-07-08
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,400
+20,000 vol
$0.62 each
80,000
Filed 2022-07-12 19:24
Tx date 2022-07-12
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$18,600
+30,000 vol
$0.62 each
943,296
Filed 2022-07-12 19:17
Tx date 2022-07-11
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$15,190
+24,500 vol
$0.62 each
913,296
Filed 2022-07-12 19:16
Tx date 2022-07-11
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,500
+7,500 vol
$0.60 each
888,796
Filed 2022-05-10 19:27
Tx date 2022-05-06
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$19,950
+28,500 vol
$0.70 each
35,033
Filed 2022-05-05 12:00
Tx date 2022-05-02
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+3,333 vol
6,533
Filed 2022-05-05 11:59
Tx date 2022-05-02
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-3,333 vol
16,667
Filed 2022-05-05 11:55
Tx date 2022-05-02
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+16,667 vol
102,703
Filed 2022-05-05 11:54
Tx date 2022-05-02
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-16,667 vol
138,332
Filed 2022-03-07 14:33
Tx date 2022-03-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+16,667 vol
86,036
Filed 2022-03-07 14:32
Tx date 2022-03-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-16,667 vol
154,999
Filed 2022-01-13 14:10
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+11,667 vol
11,667
Filed 2022-01-13 14:10
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2022-01-13 14:09
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-11,667 vol
28,333
Filed 2022-01-13 14:06
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+11,667 vol
11,667
Filed 2022-01-13 14:04
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2022-01-13 14:03
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-11,667 vol
28,333
Filed 2022-01-13 13:56
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+13,333 vol
297,999
Filed 2022-01-13 13:53
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-13,333 vol
37,001
Filed 2022-01-13 13:50
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+13,333 vol
149,801
Filed 2022-01-13 13:49
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-13,333 vol
37,001
Filed 2022-01-13 13:45
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+11,667 vol
69,369
Filed 2022-01-13 13:44
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-11,667 vol
171,666
Filed 2022-01-13 13:39
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
57 - Exercise of rights

+20,783 vol
74,976
Filed 2022-01-13 13:36
Tx date 2022-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Restricted Share Units
57 - Exercise of rights

-20,783 vol
123,917
Filed 2021-12-01 23:39
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+5,333 vol
284,666
Filed 2021-12-01 23:38
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-5,333 vol
50,334
Filed 2021-12-01 23:35
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+5,333 vol
136,468
Filed 2021-12-01 23:34
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-5,333 vol
50,334
Filed 2021-12-01 23:30
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+5,333 vol
502,360
Filed 2021-12-01 23:29
Tx date 2021-11-29
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-5,333 vol
50,334
Filed 2021-11-19 22:39
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Indirect Ownership)
Restricted Share Units
56 - Grant of rights

+20,000 vol
144,700
Filed 2021-11-19 20:54
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+10,000 vol
20,000
Filed 2021-11-19 20:47
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+30,000 vol
245,700
Filed 2021-11-19 20:45
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+30,000 vol
227,700
Filed 2021-11-19 20:42
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+30,000 vol
183,333
Filed 2021-11-19 20:39
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+75,000 vol
1,164,200
Filed 2021-11-19 20:33
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+85,000 vol
1,277,200
Filed 2021-11-19 20:29
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
40,000
Filed 2021-11-19 20:27
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
40,000
Filed 2021-11-19 20:24
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
55,667
Filed 2021-11-19 20:22
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
97,000
Filed 2021-11-19 20:19
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
55,667
Filed 2021-11-19 20:15
Tx date 2021-11-15
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+5,000 vol
55,667
Filed 2021-11-16 14:21
Tx date 2021-11-10
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$45,000
+50,000 vol
$0.90 each
497,027
Filed 2021-11-07 18:59
Tx date 2021-11-03
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$24,385
+25,000 vol
$0.98 each
447,027
Filed 2021-11-03 16:59
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$23,265
+23,500 vol
$0.99 each
279,333
Filed 2021-11-03 16:58
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,430
+3,500 vol
$0.98 each
255,833
Filed 2021-11-03 16:58
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$960.00
+1,000 vol
$0.96 each
252,333
Filed 2021-11-03 16:57
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$6,175
+6,500 vol
$0.95 each
251,333
Filed 2021-11-03 16:56
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$19,740
+21,000 vol
$0.94 each
244,833
Filed 2021-11-03 16:55
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$4,650
+5,000 vol
$0.93 each
223,833
Filed 2021-11-03 16:55
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,275
+2,500 vol
$0.91 each
218,833
Filed 2021-11-03 16:54
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$22,250
+25,000 vol
$0.89 each
216,333
Filed 2021-11-02 15:50
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,403
+2,700 vol
$0.89 each
3,200
Filed 2021-11-02 15:42
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$435.00
+500 vol
$0.87 each
500
Filed 2021-11-02 15:37
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2021-11-02 15:36
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stegic, Ana
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
10,000
Filed 2021-11-02 11:36
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,450
+17,000 vol
$0.85 each
1,921,076
Filed 2021-11-02 11:36
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$27,720
+33,000 vol
$0.84 each
1,904,076
Filed 2021-11-02 11:33
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$23,500
+25,000 vol
$0.94 each
422,027
Filed 2021-11-01 19:37
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$9,999
+13,888 vol
$0.72 each
57,702
Filed 2021-11-01 19:27
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$33,320
+34,000 vol
$0.98 each
881,296
Filed 2021-11-01 19:26
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$26,600
+28,000 vol
$0.95 each
847,296
Filed 2021-11-01 19:25
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,290
+3,500 vol
$0.94 each
819,296
Filed 2021-11-01 19:24
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$34,410
+37,000 vol
$0.93 each
815,796
Filed 2021-11-01 19:23
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$2,300
+2,500 vol
$0.92 each
778,796
Filed 2021-11-01 13:37
Tx date 2021-11-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,440
+13,000 vol
$0.88 each
60,000
Filed 2021-10-13 22:22
Tx date 2021-05-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+16,667 vol
26,471
Filed 2021-10-13 22:21
Tx date 2021-05-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-16,667 vol
153,333
Filed 2021-10-13 22:19
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+50,000 vol
170,000
Filed 2021-10-13 17:19
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+12,000 vol
191,333
Filed 2021-10-13 17:18
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-12,000 vol
50,667
Filed 2021-10-13 17:14
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+12,000 vol
131,135
Filed 2021-10-13 17:13
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-12,000 vol
50,667
Filed 2021-10-13 17:10
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+12,000 vol
397,027
Filed 2021-10-13 17:08
Tx date 2021-10-04
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-12,000 vol
50,667
Filed 2021-08-05 18:10
Tx date 2021-08-05
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,864
+17,343 vol
$0.86 each
27,147
Filed 2021-08-05 18:06
Tx date 2021-08-05
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,240
+3,000 vol
$1.08 each
47,000
Filed 2021-08-05 18:05
Tx date 2021-08-05
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$7,420
+7,000 vol
$1.06 each
44,000
Filed 2021-08-05 18:02
Tx date 2021-08-04
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,750
+12,500 vol
$1.02 each
776,296
Filed 2021-08-05 17:58
Tx date 2021-08-04
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$10,712
+10,300 vol
$1.04 each
1,871,076
Filed 2021-07-15 20:20
Tx date 2021-07-14
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$8,892
+2,600 vol
$3.42 each
37,000
Filed 2021-07-15 19:57
Tx date 2021-07-13
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,280
+4,000 vol
$3.57 each
763,796
Filed 2021-07-04 17:24
Tx date 2021-06-30
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,985
+3,500 vol
$3.71 each
34,400
Filed 2021-07-04 17:20
Tx date 2021-06-30
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$14,800
+4,000 vol
$3.70 each
759,796
Filed 2021-06-06 16:28
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$182,672
+41,296 vol
$4.42 each
54,193
Filed 2021-06-06 16:26
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$77,636
+17,551 vol
$4.42 each
26,662
Filed 2021-06-06 16:22
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$306,889
+69,377 vol
$4.42 each
119,135
Filed 2021-06-06 16:18
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$1,460,188
+330,098 vol
$4.42 each
442,729
Filed 2021-06-06 16:16
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$6,620,347
+1,496,631 vol
$4.42 each
1,860,776
Filed 2021-06-06 16:11
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$205,506
+46,458 vol
$4.42 each
126,100
Filed 2021-06-06 16:09
Tx date 2021-06-02
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$2,637,909
+596,340 vol
$4.42 each
830,796
Filed 2021-06-06 16:02
Tx date 2021-06-03
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-300,300
-75,000 vol
$4.00 each
755,796
Filed 2021-06-06 15:55
Tx date 2021-06-03
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-400,300
-100,000 vol
$4.00 each
385,027
Filed 2021-03-06 12:50
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$3,002
+583 vol
$5.15 each
9,111
Filed 2021-03-06 12:48
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$7,065
+1,372 vol
$5.15 each
12,897
Filed 2021-03-06 12:45
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$38,861
+7,546 vol
$5.15 each
79,642
Filed 2021-03-06 12:44
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$153,171
+29,742 vol
$5.15 each
234,456
Filed 2021-03-06 12:40
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$256,104
+49,729 vol
$5.15 each
364,145
Filed 2021-03-06 12:39
Tx date 2021-03-03
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$56,480
+10,967 vol
$5.15 each
112,631
Filed 2021-03-03 20:20
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$8,977
+1,697 vol
$5.29 each
8,528
Filed 2021-03-03 20:17
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$21,128
+3,994 vol
$5.29 each
11,525
Filed 2021-03-03 20:13
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$116,210
+21,968 vol
$5.29 each
72,096
Filed 2021-03-03 20:12
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$457,987
+86,576 vol
$5.29 each
204,714
Filed 2021-03-03 20:08
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$765,775
+144,759 vol
$5.29 each
314,416
Filed 2021-03-03 20:07
Tx date 2021-03-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$168,893
+31,927 vol
$5.29 each
101,664
Filed 2021-02-27 17:11
Tx date 2021-02-25
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+10,833 vol
13,650
Filed 2021-02-27 17:10
Tx date 2021-02-25
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-10,833 vol
86,167
Filed 2021-02-27 17:03
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$10,086
+1,581 vol
$6.38 each
6,831
Filed 2021-02-27 17:00
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$23,739
+3,721 vol
$6.38 each
7,531
Filed 2021-02-27 16:55
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$130,541
+20,461 vol
$6.38 each
50,128
Filed 2021-02-27 16:54
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$514,470
+80,638 vol
$6.38 each
118,138
Filed 2021-02-27 16:49
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$71,296
+11,175 vol
$6.38 each
49,758
Filed 2021-02-27 16:45
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$860,215
+134,830 vol
$6.38 each
169,657
Filed 2021-02-27 16:43
Tx date 2021-02-23
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Common Shares
11 - Acquisition or disposition carried out privately
$189,722
+29,737 vol
$6.38 each
69,737
Filed 2021-01-15 21:39
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+35,000 vol
35,000
Filed 2021-01-15 21:39
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
McNealey, Jennifer
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 19:01
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+40,000 vol
62,667
Filed 2021-01-15 18:58
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Restricted Share Units
56 - Grant of rights

+124,700 vol
124,700
Filed 2021-01-15 18:57
Tx date 2015-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 18:55
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+484,200 vol
1,089,200
Filed 2021-01-15 18:52
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+102,700 vol
197,700
Filed 2021-01-15 18:49
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+70,000 vol
120,000
Filed 2021-01-15 18:47
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+40,000 vol
62,667
Filed 2021-01-15 18:44
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+513,200 vol
1,192,200
Filed 2021-01-15 18:41
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+40,000 vol
92,000
Filed 2021-01-15 18:37
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+35,000 vol
35,000
Filed 2021-01-15 18:36
Tx date 2020-11-24
$ATE
Antibe Therapeutics Inc.
Hoffman, Robert
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2021-01-15 17:48
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+40,000 vol
62,667
Filed 2021-01-15 17:45
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+102,700 vol
215,700
Filed 2021-01-15 17:39
Tx date 2021-01-11
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+64,500 vol
97,000
Filed 2021-01-03 16:05
Tx date 2020-12-31
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Common Shares
57 - Exercise of rights

+2,500 vol
23,500
Filed 2021-01-03 16:04
Tx date 2020-12-31
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights

-2,500 vol
5,000
Filed 2020-12-17 18:50
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-204,000 vol
22,667
Filed 2020-12-17 18:49
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-180,000 vol
20,000
Filed 2020-12-17 18:48
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Holder: NFQ Ventures Ltd (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-2,160,000 vol
240,000
Filed 2020-12-17 18:47
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-1,614,000 vol
179,333
Filed 2020-12-17 18:45
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-1,417,500 vol
157,500
Filed 2020-12-17 18:44
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-630,000 vol
70,000
Filed 2020-12-17 18:43
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
37 - Stock split or consolidation

-34,290 vol
3,810
Filed 2020-12-17 18:42
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-192,763 vol
21,418
Filed 2020-12-17 18:40
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-5,445,000 vol
605,000
Filed 2020-12-17 18:39
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-2,790,000 vol
310,000
Filed 2020-12-17 18:38
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-360,000 vol
40,000
Filed 2020-12-17 18:37
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-313,443 vol
34,827
Filed 2020-12-17 18:35
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-855,000 vol
95,000
Filed 2020-12-17 18:34
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-594,000 vol
66,000
Filed 2020-12-17 18:33
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-47,250 vol
5,250
Filed 2020-12-17 18:31
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-450,000 vol
50,000
Filed 2020-12-17 18:30
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-88,235 vol
9,804
Filed 2020-12-17 18:28
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Warrants
37 - Stock split or consolidation

-75,000 vol
8,333
Filed 2020-12-17 18:27
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-204,000 vol
22,667
Filed 2020-12-17 18:26
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-472,500 vol
52,500
Filed 2020-12-17 18:25
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-4,365,240 vol
485,027
Filed 2020-12-17 18:23
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
37 - Stock split or consolidation

-51,750 vol
5,750
Filed 2020-12-17 18:21
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-6,111,000 vol
679,000
Filed 2020-12-17 18:20
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-3,042,185 vol
338,021
Filed 2020-12-17 18:19
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-266,999 vol
29,667
Filed 2020-12-17 18:17
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-337,500 vol
37,500
Filed 2020-12-17 18:15
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-468,000 vol
52,000
Filed 2020-12-17 18:12
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-204,000 vol
22,667
Filed 2020-12-17 18:11
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-303,757 vol
33,751
Filed 2020-12-17 18:10
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-347,242 vol
38,583
Filed 2020-12-17 18:08
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-1,017,000 vol
113,000
Filed 2020-12-17 18:06
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Options
37 - Stock split or consolidation

-630,000 vol
70,000
Filed 2020-12-17 18:05
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-278,100 vol
30,900
Filed 2020-12-17 18:01
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Restricted Share Units
37 - Stock split or consolidation

-67,500 vol
7,500
Filed 2020-12-17 17:59
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
37 - Stock split or consolidation

-292,500 vol
32,500
Filed 2020-12-17 17:58
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-189,000 vol
21,000
Filed 2020-12-17 17:56
Tx date 2020-12-01
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-25,352 vol
2,817
Filed 2020-12-17 14:50
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+53,333 vol
1,793,333
Filed 2020-12-17 14:49
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-53,333 vol
226,667
Filed 2020-12-17 14:47
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+53,333 vol
4,850,267
Filed 2020-12-17 14:46
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-53,333 vol
226,667
Filed 2020-12-17 14:42
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+53,333 vol
385,825
Filed 2020-12-17 14:41
Tx date 2020-11-30
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-53,333 vol
226,667
Filed 2020-10-08 22:45
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
1,740,000
Filed 2020-10-08 22:43
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
280,000
Filed 2020-10-08 22:40
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
4,796,934
Filed 2020-10-08 22:38
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
280,000
Filed 2020-10-08 22:32
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
332,492
Filed 2020-10-08 22:31
Tx date 2020-10-05
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
280,000
Filed 2020-10-05 22:09
Tx date 2020-09-30
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Common Shares
57 - Exercise of rights

+25,000 vol
210,000
Filed 2020-10-05 22:07
Tx date 2020-09-30
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights

-25,000 vol
75,000
Filed 2020-09-25 20:05
Tx date 2020-09-24
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$33,333
+98,039 vol
$0.34 each
98,039
Filed 2020-09-25 14:50
Tx date 2020-09-24
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$17,850
+52,500 vol
$0.34 each
52,500
Filed 2020-09-24 13:28
Tx date 2020-09-24
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$25,500
+75,000 vol
$0.34 each
375,000
Filed 2020-09-23 15:21
Tx date 2020-09-22
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$26,455
+71,500 vol
$0.37 each
348,270
Filed 2020-09-22 13:59
Tx date 2020-09-21
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$10,500
+30,000 vol
$0.35 each
309,000
Filed 2020-09-22 13:48
Tx date 2020-09-21
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$10,140
+28,169 vol
$0.36 each
28,169
Filed 2020-09-22 13:46
Tx date 2020-05-11
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2020-07-02 13:41
Tx date 2020-06-30
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Common Shares
57 - Exercise of rights

+25,000 vol
185,000
Filed 2020-07-02 13:39
Tx date 2020-06-30
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Restricted Share Units
57 - Exercise of rights

-25,000 vol
100,000
Filed 2020-06-15 13:03
Tx date 2020-06-11
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+500,000 vol
500,000
Filed 2020-06-06 14:41
Tx date 2020-06-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Holder: NFQ Ventures Ltd (Indirect Ownership)
Common Shares
54 - Exercise of warrants
$75,000
+500,000 vol
$0.15 each
2,400,000
Filed 2020-06-06 14:40
Tx date 2020-06-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Holder: NFQ Ventures Ltd (Indirect Ownership)
Warrants
54 - Exercise of warrants
$-75,000
-500,000 vol
$0.15 each
0
Filed 2020-06-06 14:35
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$28,999
+200,000 vol
$0.145 each
214,181
Filed 2020-06-06 14:34
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-29,000
-200,000 vol
$0.145 each
700,000
Filed 2020-06-06 14:30
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-91,500
-150,000 vol
$0.61 each
212,492
Filed 2020-06-06 14:29
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$49,500
+150,000 vol
$0.33 each
362,492
Filed 2020-06-06 14:28
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Options
51 - Exercise of options
$-49,500
-150,000 vol
$0.33 each
337,508
Filed 2020-06-06 14:24
Tx date 2020-06-02
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-32,450
-55,000 vol
$0.59 each
0
Filed 2020-06-06 14:23
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-90,000
-150,000 vol
$0.60 each
55,000
Filed 2020-06-06 14:21
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$49,500
+150,000 vol
$0.33 each
205,000
Filed 2020-06-06 14:21
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-49,500
-150,000 vol
$0.33 each
660,000
Filed 2020-06-06 14:16
Tx date 2020-06-05
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
54 - Exercise of warrants
$4,950
+33,000 vol
$0.15 each
279,000
Filed 2020-06-06 14:15
Tx date 2020-06-05
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Warrants
54 - Exercise of warrants
$-4,950
-33,000 vol
$0.15 each
0
Filed 2020-06-06 14:12
Tx date 2020-06-03
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-14,640
-24,000 vol
$0.61 each
246,000
Filed 2020-06-06 14:10
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-125,000
-200,000 vol
$0.63 each
270,000
Filed 2020-06-06 14:09
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$21,750
+150,000 vol
$0.145 each
470,000
Filed 2020-06-06 14:07
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-21,750
-150,000 vol
$0.145 each
700,000
Filed 2020-06-06 13:57
Tx date 2020-06-04
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-135,000
-225,000 vol
$0.60 each
300,000
Filed 2020-06-06 13:57
Tx date 2020-06-03
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-156,997.50
-259,500 vol
$0.60 each
525,000
Filed 2020-06-06 13:55
Tx date 2020-06-02
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-9,300
-15,500 vol
$0.60 each
784,500
Filed 2020-06-06 13:55
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-762,500
-1,250,000 vol
$0.61 each
800,000
Filed 2020-06-06 13:52
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$145,000
+1,000,000 vol
$0.145 each
2,050,000
Filed 2020-06-06 13:51
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$247,500
+750,000 vol
$0.33 each
1,050,000
Filed 2020-06-06 13:49
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-145,000
-1,000,000 vol
$0.145 each
3,380,206
Filed 2020-06-06 13:47
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-247,500
-750,000 vol
$0.33 each
4,380,206
Filed 2020-06-06 13:39
Tx date 2020-06-04
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-77,100
-128,500 vol
$0.60 each
400,000
Filed 2020-06-06 13:37
Tx date 2020-06-02
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-57,900
-96,500 vol
$0.60 each
528,500
Filed 2020-06-06 13:34
Tx date 2020-06-04
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-405,000
-675,000 vol
$0.60 each
276,770
Filed 2020-06-06 13:33
Tx date 2020-06-02
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-105,000
-175,000 vol
$0.60 each
951,770
Filed 2020-06-06 13:31
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-990,000
-1,650,000 vol
$0.60 each
1,126,770
Filed 2020-06-06 13:28
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$181,250
+1,250,000 vol
$0.145 each
2,776,770
Filed 2020-06-06 13:27
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$28,000
+200,000 vol
$0.14 each
1,526,770
Filed 2020-06-06 13:26
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
51 - Exercise of options
$346,500
+1,050,000 vol
$0.33 each
1,326,770
Filed 2020-06-06 13:23
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-181,250
-1,250,000 vol
$0.145 each
3,100,000
Filed 2020-06-06 13:21
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-28,000
-200,000 vol
$0.14 each
4,350,000
Filed 2020-06-06 13:20
Tx date 2020-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Options
51 - Exercise of options
$-346,500
-1,050,000 vol
$0.33 each
4,550,000
Filed 2020-05-19 21:32
Tx date 2020-05-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2020-05-19 21:32
Tx date 2020-05-01
$ATE
Antibe Therapeutics Inc.
Stauffer, Joseph
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2020-05-19 17:24
Tx date 2020-05-11
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
125,000
Filed 2020-05-19 17:22
Tx date 2020-05-11
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
325,000
Filed 2020-05-19 17:18
Tx date 2020-05-11
$ATE
Antibe Therapeutics Inc.
Batal, Rami
5 - Senior Officer of Issuer
Holder: 2107197 Ontario Inc (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
160,000
Filed 2019-11-28 13:32
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+400,000 vol
950,000
Filed 2019-11-28 13:29
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+400,000 vol
1,130,000
Filed 2019-11-28 13:26
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+475,000 vol
1,575,000
Filed 2019-11-28 13:23
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+1,850,000 vol
6,050,000
Filed 2019-11-28 13:19
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+2,040,000 vol
6,790,000
Filed 2019-11-28 13:16
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+160,000 vol
400,000
Filed 2019-11-28 13:12
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+160,000 vol
520,000
Filed 2019-11-28 13:06
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+160,000 vol
400,000
Filed 2019-11-28 12:56
Tx date 2019-11-28
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
56 - Grant of rights

+160,000 vol
400,000
Filed 2019-11-06 12:36
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Brouard, Éric Stéphane
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
57 - Exercise of rights
$22,749
+58,333 vol
$0.39 each
58,333
Filed 2019-11-06 12:34
Tx date 2018-10-22
$ATE
Antibe Therapeutics Inc.
Brouard, Éric Stéphane
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2019-11-06 12:21
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Brouard, Éric Stéphane
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-58,333 vol
116,667
Filed 2019-10-29 12:07
Tx date 2019-10-24
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-53,400
-120,000 vol
$0.445 each
212,492
Filed 2019-10-18 12:19
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
McMillan, Michael
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
57 - Exercise of rights

+66,667 vol
4,339,187
Filed 2019-10-18 12:18
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
McMillan, Michael
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-66,667 vol
533,333
Filed 2019-10-18 12:06
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Bourgeois, Nicolas
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
57 - Exercise of rights

+66,667 vol
4,339,187
Filed 2019-10-18 12:04
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Bourgeois, Nicolas
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-66,667 vol
533,333
Filed 2019-10-10 16:06
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
1,620,000
Filed 2019-10-10 16:05
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
240,000
Filed 2019-10-10 16:01
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
4,676,934
Filed 2019-10-10 15:59
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
240,000
Filed 2019-10-10 15:53
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+120,000 vol
332,492
Filed 2019-10-10 15:50
Tx date 2019-10-03
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
57 - Exercise of rights

-120,000 vol
240,000
Filed 2019-09-17 12:25
Tx date 2019-09-16
$ATE
Antibe Therapeutics Inc.
Binnie, Craig
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:24
Tx date 2019-09-16
$ATE
Antibe Therapeutics Inc.
Binnie, Craig
5 - Senior Officer of Issuer
Direct Ownership
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:23
Tx date 2019-09-16
$ATE
Antibe Therapeutics Inc.
Binnie, Craig
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2019-09-17 12:21
Tx date 2019-09-16
$ATE
Antibe Therapeutics Inc.
Binnie, Craig
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2019-08-14 14:09
Tx date 2019-08-13
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
15 - Acquisition or disposition under a prospectus
$5,250
+17,500 vol
$0.30 each
57,500
Filed 2019-08-14 14:07
Tx date 2019-08-13
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
15 - Acquisition or disposition under a prospectus
$10,500
+35,000 vol
$0.30 each
300,000
Filed 2019-08-13 14:31
Tx date 2019-08-13
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Warrants
15 - Acquisition or disposition under a prospectus
$24,999
+83,333 vol
$0.30 each
83,333
Filed 2019-08-13 14:25
Tx date 2019-08-13
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
15 - Acquisition or disposition under a prospectus
$50,000
+166,667 vol
$0.30 each
4,556,934
Filed 2019-06-03 12:42
Tx date 2019-06-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: AltaPharm International Inc. (Control or Direction)
Warrants
55 - Expiration of warrants

-300,000 vol
0
Filed 2019-06-03 12:30
Tx date 2019-06-01
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Holder: Schmed Enterprises Inc. (Control or Direction)
Warrants
55 - Expiration of warrants

-180,000 vol
0
Filed 2019-06-03 12:18
Tx date 2019-06-01
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Warrants
55 - Expiration of warrants

-120,000 vol
0
Filed 2019-05-17 12:23
Tx date 2019-05-17
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$7,000
+20,000 vol
$0.35 each
320,000
Filed 2019-05-16 16:20
Tx date 2019-05-14
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,400
+10,000 vol
$0.34 each
276,770
Filed 2019-05-13 15:17
Tx date 2019-05-13
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$11,900
+35,000 vol
$0.34 each
265,000
Filed 2019-02-27
Tx date 2019-02-25
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
15 - Acquisition or disposition under a prospectus
$20,000
+80,000 vol
$0.25 each
230,000
Filed 2019-02-27
Tx date 2019-02-25
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
15 - Acquisition or disposition under a prospectus
$10,000
+40,000 vol
$0.25 each
40,000
Filed 2019-02-27
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2018-12-13
Tx date 2018-12-13
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Holder: NFQ Ventures Ltd (Indirect Ownership)
Common Shares
54 - Exercise of warrants
$66,000
+300,000 vol
$0.22 each
1,900,000
Filed 2018-12-13
Tx date 2018-12-13
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Holder: NFQ Ventures Ltd (Indirect Ownership)
Warrants
54 - Exercise of warrants
$-66,000
-300,000 vol
$0.22 each
500,000
Filed 2018-11-28
Tx date 2018-11-27
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$12,500
+50,000 vol
$0.25 each
150,000
Filed 2018-10-24
Tx date 2018-10-22
$ATE
Antibe Therapeutics Inc.
Brouard, Éric Stéphane
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
79,000
Filed 2018-10-24
Tx date 2018-10-22
$ATE
Antibe Therapeutics Inc.
Brouard, Éric Stéphane
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
175,000
Filed 2018-10-11
Tx date 2018-10-10
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$18,700
+55,000 vol
$0.34 each
55,000
Filed 2018-10-05
Tx date 2015-10-15
$ATE
Antibe Therapeutics Inc.
McMillan, Michael
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2015-10-15
$ATE
Antibe Therapeutics Inc.
Bourgeois, Nicolas
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+4,750,000 vol
4,750,000
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+360,000 vol
360,000
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+4,200,000 vol
4,200,000
Filed 2018-10-05
Tx date 2016-01-01
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2015-12-01
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+360,000 vol
360,000
Filed 2018-10-05
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Bourgeois, Nicolas
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
97 - Other

+600,000 vol
600,000
Filed 2018-10-05
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2016-07-18
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+550,000 vol
550,000
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
McMillan, Michael
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Restricted Share Units
97 - Other

+600,000 vol
600,000
Filed 2018-10-05
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+360,000 vol
360,000
Filed 2018-10-05
Tx date 2018-03-19
$ATE
Antibe Therapeutics Inc.
Khouri, Amal
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+360,000 vol
360,000
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+730,000 vol
730,000
Filed 2018-10-05
Tx date 2018-10-03
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Direct Ownership
Restricted Share Units
97 - Other

+1,100,000 vol
1,100,000
Filed 2018-10-05
Tx date 2013-06-10
$ATE
Antibe Therapeutics Inc.
Flower, Roderick John
4 - Director of Issuer
Direct Ownership
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
Filed 2018-10-02
Tx date 2018-09-28
$ATE
Antibe Therapeutics Inc.
Macnee, Walter Minnes
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$51,000
+150,000 vol
$0.34 each
4,390,267
Filed 2018-09-24
Tx date 2018-09-24
$ATE
Antibe Therapeutics Inc.
McMillan, Michael
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$30,819
+100,000 vol
$0.3082 each
4,272,520
Filed 2018-09-20
Tx date 2018-09-19
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$27,000
+100,000 vol
$0.27 each
266,770
Filed 2018-09-19
Tx date 2018-09-18
$ATE
Antibe Therapeutics Inc.
Curtis, Scott Wilson
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$13,000
+50,000 vol
$0.26 each
300,000
Filed 2018-09-19
Tx date 2018-09-19
$ATE
Antibe Therapeutics Inc.
Wilson, Alain
5 - Senior Officer of Issuer
Holder: The Elegen Group Inc. (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$9,450
+35,000 vol
$0.27 each
38,100
Filed 2018-09-19
Tx date 2018-09-19
$ATE
Antibe Therapeutics Inc.
Legault, Daniel Marcel
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$26,000
+100,000 vol
$0.26 each
100,000
Filed 2018-09-18
Tx date 2018-09-18
$ATE
Antibe Therapeutics Inc.
Bourgeois, Nicolas
7 - Director or Senior Officer of Insider or Subsidiary of Issuer (other than in 4,5,6)
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$26,170
+100,000 vol
$0.2617 each
4,272,520
Filed 2018-06-10
Tx date 2018-06-07
$ATE
Antibe Therapeutics Inc.
Buret, Andre Gerald
6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Common Shares
54 - Exercise of warrants
$7,500
+50,000 vol
$0.15 each
210,000
Filed 2018-06-10
Tx date 2018-06-07
$ATE
Antibe Therapeutics Inc.
Buret, Andre Gerald
6 - Director or Senior Officer of 10% Security Holder
Direct Ownership
Warrants
54 - Exercise of warrants
$-7,500
-50,000 vol
$0.15 each
0
Filed 2018-06-10
Tx date 2018-06-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Warrants
54 - Exercise of warrants
$-75,000
-500,000 vol
$0.15 each
0
Filed 2018-06-10
Tx date 2018-06-05
$ATE
Antibe Therapeutics Inc.
Wu, Yung Cheng
4 - Director of Issuer
Direct Ownership
Common Shares
54 - Exercise of warrants
$75,000
+500,000 vol
$0.15 each
1,500,000
Filed 2018-05-02
Tx date 2018-05-01
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-71,820
-189,000 vol
$0.38 each
166,770
Filed 2018-04-28
Tx date 2018-04-26
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-96,965
-236,500 vol
$0.41 each
430,270
Filed 2018-04-28
Tx date 2018-04-27
$ATE
Antibe Therapeutics Inc.
Wallace, John Lawrence
4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-30,545
-74,500 vol
$0.41 each
355,770
Filed 2018-04-28
Tx date 2018-04-24
$ATE
Antibe Therapeutics Inc.
Vaughan, David James
5 - Senior Officer of Issuer